Advertisement
U.S. markets open in 8 hours 27 minutes

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.6600-0.3400 (-6.80%)
At close: 04:00PM EDT
3.6500 -1.01 (-21.67%)
After hours: 07:57PM EDT

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424-248-6500
https://www.pumabiotechnology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees185

Key Executives

NameTitlePayExercisedYear Born
Mr. Alan H. AuerbachFounder, Chairman, President, CEO & Secretary1.74MN/A1970
Mr. Maximo F. NouguesCFO & Principal Accounting Officer781.47kN/A1969
Dr. Alvin F. Wong Pharm.d.Chief Scientific Officer809.69kN/A1953
Mr. Douglas Hunt B.Sc., FRAPSSenior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law632.65kN/A1965
Mr. Jeffrey Jerome LudwigChief Commercial Officer916.85kN/A1966
Mr. Mariann OhanesianSenior Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Corporate Governance

Puma Biotechnology, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.